Literature DB >> 3267455

Postconfluency MDCK monolayers as an in vitro model of solid tumor chemosensitivity.

P Skehan1, J Thomas, S J Friedman.   

Abstract

Shortly after reaching confluency, canine MDCK cells enter a prolonged state of basal growth with doubling times of 200-300 hours. These values are similar to those commonly exhibited by in vivo solid tumors at clinically relevant sizes. By comparison with rapidly growing sparse density cultures, the postconfluent monolayers displayed a pronounced resistance to deazauridine, deoxyspergualin, and 5-fluorouridine. Drug concentrations required for unit levels of effect increased from several fold to several orders of magnitude as cells entered high density basal growth. This high density chemoresistance was observed for both growth inhibition and cytotoxicity, but was much more pronounced with the former. Dose-response curves were biphasic, suggesting that growth inhibition and cytotoxicity may be mediated by different mechanisms of drug action. The pronounced chemoresistance of postconfluent MDCK monolayers is similar to that encountered with many clinical solid neoplasms. It suggests that postconfluency monolayers, like multicellular spheroids and cellular multilayers, may provide better in vitro models of solid tumor chemosensitivity than subconfluent monolayer and suspension cultures.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3267455     DOI: 10.1007/bf00121851

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  23 in total

1.  On the regulation of cell growth in culture.

Authors:  P Skehan
Journal:  Exp Cell Res       Date:  1976-01       Impact factor: 3.905

2.  Tumor chemotherapy: efficacy dependent on mode of growth.

Authors:  R F Hagemann; L L Schenken; S Lesher
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

Review 3.  Quantitative cytokinetics: cellular response to cell cycle specific agents.

Authors:  J W Gray
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

4.  Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents.

Authors:  A A Ovejera; D P Houchens
Journal:  Semin Oncol       Date:  1981-12       Impact factor: 4.929

5.  A rapid naphthol yellow S method for measuring the cellular protein content of anchorage cultures.

Authors:  P Skehan; S J Friedman
Journal:  In Vitro Cell Dev Biol       Date:  1985-05

6.  Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect.

Authors:  H E Skipper; F M Schabel
Journal:  Cancer Treat Rep       Date:  1984-01

7.  Human tumor colony assay and chemosensitivity testing.

Authors:  S E Salmon
Journal:  Cancer Treat Rep       Date:  1984-01

Review 8.  Dihydroxyanthraquinone and related bis(substituted) aminoanthraquinones: a novel class of antitumor agents.

Authors:  F Traganos
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

Review 9.  Bleomycin--mode of action with particular reference to the cell cycle.

Authors:  P R Twentyman
Journal:  Pharmacol Ther       Date:  1983       Impact factor: 12.310

10.  The response to cytotoxic drugs of EMT6 cells treated either as intact or disaggregated spheroids.

Authors:  T T Kwok; P R Twentyman
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

View more
  3 in total

1.  Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.

Authors:  G Bernhardt; H Reile; H Birnböck; T Spruss; H Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

2.  Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates.

Authors:  P E Pizao; D M Lyaruu; G J Peters; J van Ark-Otte; B Winograd; G Giaccone; H M Pinedo
Journal:  Br J Cancer       Date:  1992-10       Impact factor: 7.640

3.  Multilayered Cultures of NSCLC cells grown at the Air-Liquid Interface allow the efficacy testing of inhaled anti-cancer drugs.

Authors:  Dania Movia; Despina Bazou; Yuri Volkov; Adriele Prina-Mello
Journal:  Sci Rep       Date:  2018-08-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.